Starc II, a multicenter randomized placebo-controlled double-blind clinical trial of trapidil for 1-year clinical events and angiographic restenosis reduction after coronary angioplasty and stenting

Catheterization and Cardiovascular Interventions

Volumn 64, Issue 3, 2005, Pages 375-382

  Maresta, Aleardo ^a   Balducelli, M ^a   Latini, R ^b,c   Bernardi, G ^d   Moccetti, T ^e   Sosa, C ^b   Barlera, S ^b   Varani, E ^a   Ribeiro Da Silva, E E ^f   Monici Preti, A ^g   Maggioni, A P ^h  

^a SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c NEW YORK MEDICAL COLLEGE   (United States)

^d SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^e DIVISION OF CARDIOLOGY   (Switzerland)

^f Hospital Unicor   (Brazil)

^g CHIESI FARMACEUTICI S P A   (Italy)

^h ANMCO RESEARCH CENTER   (Italy)

Author keywords

Balloon angioplasty; Quantitative coronary angiography; Randomized trial; Stent; Trapidil

Indexed keywords

ACETYLSALICYLIC ACID; HEPARIN; TICLOPIDINE; TRAPIDIL;

ADULT; AGED; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; DEATH; DETERIORATION; DIGESTIVE SYSTEM FUNCTION DISORDER; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOMES RESEARCH; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RESTENOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; BLOOD VESSEL PROSTHESIS IMPLANTATION; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PATIENT COMPLIANCE; PLATELET AGGREGATION INHIBITORS; SAFETY; STENTS; TICLOPIDINE; TRAPIDIL; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 20044386653     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.20290     Document Type: Article

References (19)

1. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M, Cleman M, Heuser R, Almond D, Teirstein PS, Fish RD, Colombo A, Brinker J, Moses J, Shaknovich A, Hirshfeld J, Bailey S, Ellis S, Rake R, Goldberg S, for the Stent Restenosis Study Investigators. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994;331:496-501.
2. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P, Belardi J, Sigwart U, Colombo A, Goy JJ, den Heuvel P, Delcan J, Morel M, for the Benestent Study Group. A comparison of balloon expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331:489-495.
3. Komatsu R, Ueda M, Naruko T, Kojima A, Becker AE. Neointimal tissue response at sites of coronary stenting in humans: macroscopic, histological, and immunohistochemical analyses. Circulation 1998;98:224-233.
4. Ohnishi H, Yamaguchi K, Shimasa S, Suzuki Y, Kumagai A. A new approach to treatment of atherosclerosis and trapidil as an antagonist of platelet derived growth factor. Life Sci 1992;31: 2592-2602.
5. Tiell ML, Sussmann I, Gordon PB, Sanders RN. Suppression of fibroblast proliferation in vitro and of neointimal hyperplasia in vivo by the triazolopyrimidine, trapidil. Artery 1983;12:33-50.
6. Bönisch D, Weber AA, Withpoth M, Osinski M, Schrör K. Antimitogenic effects of trapidil in coronary artery smooth muscle cells by direct activation of protein kinase. A. Mol Pharmacol 1998;54:241-248.
7. Cercek B, Ebrahimi R, Dimayuga P, Khorsandi M, Forrester JS. Trapidil prevents rat smooth muscle cell proliferation in vitro and in vivo. J Am Coll Cardiol 1991;17:72A.
8. Liu MW, Roubin GS, Robinson KA, et al. Trapidil in preventing restenosis after balloon angioplasty in the atherosclerotic rabbit. Circulation 1990:81:1089-1093.
9. Okamoto S, lnden M, Setsuda M, Konoishi T, Najano T. Effects of trapidil a platelet derived growth factor antagonist, in preventing restenosis after percutaneous transcoronary balloon angioplasty. Am Heart J 1992;123:1439-1444.
10. Maresta A, Balducelli M, Cantini L, et al. Trapidil, a platelet derived growth factor antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty: results of the randomized, double-blind STARC study. Circulation 1994;90:2710-2715.
11. Serruys PW, Foley DP, Pieper M, Kleijne JA, de Feiter PJ, on behalf of the TRAPIST investigators. The TRAPIST study: a multicenter randomized placebo controlled clinical trial of trapidil for prevention of restenosis after coronary stenting, measured by 3-D intravascular ultrasound. Eur Heart J 2001;22:1938-1947.
12. ACC/AHA Task Force Report. Guidelines for percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1993;22: 2033-2054.
13. Maresta A, Balducelli M, King SB III, Maggioni AP, Latini R, Moccetti T, Varani E, Monici Preti PM. Background and methods for the international trapidil restenosis trial after percutaneous transluminal coronary angioplasty. Cor Europaeum 1998;7:54-58.
14. Ellis SG, Pinto IM, McGillem MJ, DeBoe SF, LeFree MT, Mancini GB. Accuracy and reproducibility of quanitative coronary anteriography using 6 and 8 French catheters with cine angiographic acquisition. Cathet Cardiovasc Diagn 1991;22: 52-55.
15. Maresta A, Balducelli M, Varani E, Marzilli M, Galli C, Heiman F, Lavezzari M, Stragliotto E, De Caterina RESPRIT investigators. Prevention of post coronary angioplasty restenosis by omega-3 fatty acids: main results of the Esapent for Prevention of Restenosis Italian Study (ESPRIT). Am Heart J 2002;143:E5.
16. Wittpoth M, Bönisch D, Schrör K. Trapidil inhibits RAF-1 kinase in vascular smooth muscle cells via activation of protein kinase A (PKA). Circulation 1997;96:1558.
17. Kiesz RS, Buszman P, Martin JL, Deutsch E, Rozek MM, Gaszewska E, Rewicki M, Seweryniak P, Kosmider M, Tendera M. Local delivery of enoxaparin to decrease restenosis after stenting: results of initial multicenter trial: Polish-American Local Lovenox NIR Assessment study (the POLONIA study). Circulation 2001;103:26-31.
18. Wijns W, Schofer J, Breithardt G, Gershlick AH, Garcia E. The European multicentre, randomized, double-blind study of the sirolimus-eluting stent in the treatment of patients with de novo coronary artery lesions (E-SIRIUS): 1-year clinical outcomes. Vienna: the ESC Congress; 2003.
19. Isner JM. Vascular remodelling: honey, I think I shrunk the artery: Circulation 1994;89:2837-2941.